According to the American Cancer Society, about 35,780 new cases will be diagnosed (19,520 in men and 16,260 in women) and 12,540 deaths (7,020 in men and 5,520 in women) are expected in the United States for 2024.¹ 

Below are some links you can find on the Cell & Gene Therapy Hub and the Metasearch results section of the Multiple Myeloma page on FormularyDecisions: 

• A transformative therapy value model for rare blood diseases
• National Cancer Institute Cancer Intervention and Surveillance Modeling Network – multiple myeloma
• Update on CAR T-cell therapy in relapsed/refractory multiple myeloma
• Kidney disease in multiple myeloma and other monoclonal gammopathies: treatment and prognosis

Be sure to also reference available Product Snapshots clinical pharmacists at ForHealth Consulting team at UMass Chan Medical School, not only provide a high-level overview of the multiple myeloma treatment guidelines and ICD-10 codes, but they also include a summary of key clinical trials and Pharmacy & Therapeutics considerations.

Product surveys are an important way to share your insights with biopharma companies. Not only does your feedback communicate specific content requests to biopharma companies (eg, comparative effectiveness analysis, real-world evidence) so that they are more likely to post helpful files to FormularyDecisions, but it also helps biopharma companies identify potential evidence gaps that can be filled over time.

Log into FormularyDecisions to view all survey and feedback opportunities available. Earn points for completing surveys that can be redeemed in the form of gift cards and/or donated to a charity.

Below are links to the Product Page for surveys that are at the top of the list of all available surveys when you sort by “Most Recent” on FormularyDecisions. 

Don’t forget to also check out the following survey opportunities that may be leaving soon.

References 

1. American Cancer Society. Key statistics about multiple myeloma. Last Revised: January 19, 2024. Accessed February 27, 2024. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html 
2. Rukobia prescribing information. ViiV Healthcare; 2024. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Rukobia/pdf/RUKOBIA-PI-PIL.PDF 
3. Tyvaso DPI prescribing information. MannKind Corporation; 2023. https://www.tyvasohcp.com/static/pdf/TYVASO-DPI-PI.pdf   
4. Voquezna prescribing information. Phathom Pharmaceuticals, Inc.; 2023. https://www.phathompharma.com/wp-content/uploads/VOQUEZNA-tablets-Prescriber-Information.pdf   
5. Vowst prescribing information. Seres Therapeutics, Inc.; 2023. https://www.serestherapeutics.com/our-products/VOWST_PI.pdf  
6. Wainua prescribing information. AstraZeneca Pharmaceuticals LP; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf   
7. Zavzpret prescribing information. Pfizer, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf  
8. Akeega prescribing information. Janssen Biotech, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf   
9. Jardiance prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf   
10. Libtayo prescribing information. Regeneron Pharmaceuticals, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761097s016lbl.pdf   
11. Odomzo prescribing information. Sun Pharmaceutical Industries, Inc.; 2023. https://www.odomzo.com/themes/custom/odomzo/global/pdfs/pi.pdf   
12. Relyvrio prescribing information. Amylyx Pharmaceuticals, Inc.; 2022. https://www.amylyx.com/document/RELYVRIO-US-Prescribing-Information.pdf    
13. Vitrakvi prescribing information. Bayer HealthCare Pharmaceuticals; 2023. https://labeling.bayerhealthcare.com/html/products/pi/vitrakvi_PI.pdf   
14. Zurzuvae prescribing information. Sage Therapeutics, Inc.; 2023. https://documents.sage-biogen.com/us/zurzuvae/pi.pdf   

^a The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved.

^b The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.

FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora.  
 
The contents of this communication are non-promotional and intended exclusively for healthcare decision makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.